William Guyer's Insider Trades & SAST Disclosures
William Guyer's most recent trade in Corcept Therapeutics Inc was a trade of 32,262 Common Stock done at an average price of $74.2 . Disclosure was reported to the exchange on May 16, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern William Guyer.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 74.17 per share. | 16 May 2025 | 32,262 | 5,487 (0%) | 0% | 74.2 | 2,393,014 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2025 | 32,262 | 410,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 16 May 2025 | 32,262 | 37,749 (0%) | 0% | 21.6 | 698,472 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 06 May 2025 | 7,060 | 12,547 (0%) | 0% | 21.7 | 152,849 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2025 | 7,060 | 442,262 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 74.31 per share. | 06 May 2025 | 7,060 | 5,487 (0%) | 0% | 74.3 | 524,653 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 678 | 449,322 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 114.51 per share. | 01 Apr 2025 | 678 | 5,487 (0%) | 0% | 114.5 | 77,639 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 01 Apr 2025 | 678 | 6,165 (0%) | 0% | 21.7 | 14,679 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 140,000 | 140,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 59.07 per share. | 28 Feb 2025 | 20,000 | 5,487 (0%) | 0% | 59.1 | 1,181,400 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 28 Feb 2025 | 20,000 | 25,487 (0%) | 0% | 19.3 | 385,200 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 20,000 | 30,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.68 per share. | 02 Dec 2024 | 309 | 5,487 (0%) | 0% | 57.7 | 17,823 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 48.97 per share. | 01 Nov 2024 | 6,606 | 5,796 (0%) | 0% | 49.0 | 323,496 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 6,606 | 453,394 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 01 Nov 2024 | 6,606 | 12,402 (0%) | 0% | 21.7 | 143,020 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 3,394 | 450,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 01 Nov 2024 | 3,394 | 9,190 (0%) | 0% | 21.6 | 73,480 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 48.97 per share. | 01 Nov 2024 | 3,394 | 5,796 (0%) | 0% | 49.0 | 166,204 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 01 Oct 2024 | 10,000 | 15,796 (0%) | 0% | 21.7 | 216,500 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 10,000 | 460,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 46.28 per share. | 01 Oct 2024 | 10,000 | 5,796 (0%) | 0% | 46.3 | 462,800 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 03 Sep 2024 | 10,000 | 16,039 (0%) | 0% | 21.7 | 216,500 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 10,000 | 470,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.30 per share. | 03 Sep 2024 | 10,000 | 6,039 (0%) | 0% | 35.3 | 353,000 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.30 per share. | 03 Sep 2024 | 243 | 5,796 (0%) | 0% | 35.3 | 8,578 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 38.67 per share. | 01 Aug 2024 | 10,000 | 6,039 (0%) | 0% | 38.7 | 386,700 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 01 Aug 2024 | 10,000 | 16,039 (0%) | 0% | 21.7 | 216,500 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 10,000 | 480,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 10,000 | 490,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 01 Jul 2024 | 10,000 | 16,039 (0%) | 0% | 21.7 | 216,500 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.49 per share. | 01 Jul 2024 | 10,000 | 6,039 (0%) | 0% | 32.5 | 324,900 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 10,000 | 50,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 03 Jun 2024 | 10,000 | 16,039 (0%) | 0% | 19.3 | 192,600 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 03 Jun 2024 | 10,000 | 6,039 (0%) | 0% | 32 | 320,000 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 28 May 2024 | 30,000 | 6,039 (0%) | 0% | 32 | 960,000 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 30,000 | 60,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 28 May 2024 | 30,000 | 36,039 (0%) | 0% | 19.3 | 577,800 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.06 per share. | 01 Mar 2024 | 604 | 6,039 (0%) | 0% | 24.1 | 14,532 | Common Stock |
| Corcept Therapeutics Inc | Guyer William | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 200,000 | 200,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Guyer William | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 22 Dec 2023 | 10,000 | 16,643 (0%) | 0% | 19.3 | 192,600 | Common Stock |
| Corcept Therapeutics Inc | Guyer William | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2023 | 10,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 22 Dec 2023 | 10,000 | 6,643 (0%) | 0% | 32 | 320,000 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 25.97 per share. | 01 Dec 2023 | 609 | 6,034 (0%) | 0% | 26.0 | 15,816 | Common Stock |
| Corcept Therapeutics Inc | Guyer William | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 609 | 6,643 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 19.86 per share. | 01 Mar 2023 | 1,472 | 3,316 (0%) | 0% | 19.9 | 29,234 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 1,472 | 4,788 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 922 | 1,844 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 25.98 per share. | 01 Sep 2022 | 922 | 922 (0%) | 0% | 26.0 | 23,954 | Common Stock |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2022 | 200,000 | 200,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | William Guyer | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges